Scott EN, Hasbullah J, Carleton BC, Ross CJD.  Prevention of Adverse Drug Effects: A Pharmacogenomic Approach.  Current Opinion in Pediatrics. Curr Opin Pediatr. 2020 Oct;32(5):646-653. PMID: 32796162 DOI: 10.1097/MOP.0000000000000935 Journal Article

Chang WC, Hung SI, Carleton B, Chung WH. An Update on CYP2C9 Polymorphisms and Phenytoin Metabolism: Implications for Adverse Effects. Expert Opin Drug Metab Toxicol. 2020 Aug;16(8):723-734. PMID: 32510242 DOI: 10.1080/17425255.2020.1780209 Journal Article

Chang WC, Hung SI, Carleton B, Chung WH. An Update on CYP2C9 Polymorphisms and Phenytoin Metabolism: Implications for Adverse Effects. Expert Opin Drug Metab Toxicol. 2020 Jun 8. [Epub ahead of print] PMID: 32510242 Journal Article

Scott EN, Hasbullah J, Carleton BC, Ross CJD. Prevention of Adverse Drug Effects: A Pharmacogenomic Approach. Current Opinion in Pediatrics. 2020. (Accepted) Journal Article

Chang W, Abe R, Anderson P, Anderson W, Ardern-Jones MR, Beachkofsky TM, Bellón T, Biala AK, Bouchard C, Cavalleri GL, Chapman N, Chodosh J, Choi HK, Cibotti RR, Divito SJ, Dewar K, Dehaeck U, Etminan M, Forbes D, Fuchs E, Goldman JL, Holmes JH, Hope EA, Hung S, Hsieh C, Iovieno A, Jagdeo J, Kim MK, Koelle DM, Lacouture ME, Le Pallec S, Lehloenya RJ, Lim R, Lowe A, McCawley J, McCawley J, Micheletti RG, Mockenhaupt M, Niemeyer K, Norcross MA, Oboh D, Olteanu C, Pasieka HB, Peter J, Pirmohamed M, Rieder M, Saeed HN, Shear NH, Shieh C, Straus S, Sukasem C, Sung C, Trubiano JA, Tsou S, Ueta M, Volpi S, Wan C, Wang H, Wang Z, Weintraub J, Whale C, Wheatley LM, Whyte-Croasdaile S, Williams KB, Wright G, Yeung SN, Zhou L, Chung W, Phillips EJ, Carleton BC. SJS/TEN 2019: From Science to Translation. J Dermatol Sci. J Dermatol Sci. 2020 Apr;98(1):2-12. PMID: 32192826 10.1016/j.jdermsci.2020.02.003 Journal Article

Loucks C, Groeneweg G, Roy C, Lee DK, Rieder MJ, Lebel D, Ito S, Ross CJ, Carleton BC. Pharmacogenomic testing: the key to enhancing personalized medication use for patients. Canadian Family Physician. Can Fam Physician. 2020 Apr;66(4):241-243. PMID: 32273406  Journal Article

Wright G, Drögemöller B, Ross CJD, Carleton B. Genome-wide association studies of drug induced liver injury make progress beyond the HLA region (Letter to the Editor). Gastroenterology. 2019 Oct;157(4):1167-1168. PMID: 31348928 10.1053/j.gastro.2019.03.076 Journal Article

Drögemöller BI, Wright GEB, Lo C, Le T, Brooks B, Bhavsar AP, Rassekh SR, Ross CJD, Carleton BC. Pharmacogenomics of Cisplatin-Induced Ototoxicity: Successes, Shortcomings and Future Avenues of Research. Clin Pharm Ther. 2019 Aug;106(2):350-359. PMID: 31012503 doi: 10.1002/cpt.1483 Journal Article

Tanoshima R, Carleton BC. The Incidence of Symptomatic Osteonecrosis After Allogeneic Haematopoietic Stem Cell Transplantation in Children with Acute Lymphoblastic Leukaemia – Controversy on Dexamethasone as a Risk Factor (Letter to the Editor). Br J Haematol. 2019 Jun;185(5):958-959. PMID: 3040814510.1111/bjh.15657 Journal Article

Zazuli Z, Otten LS, Drögemöller BI, Medeiros M, Monzon JG, Wright GEB, Kollmannsberger CK, Bedard PL, Chen Z, Gelmon KA, McGoldrick N, Kitchlu A, Vijverberg SJH, Masereeuw R, Ross CJD, Liu G, Carleton BC, Maitland-van der Zee AH. Outcome Definition Influences the Relationship Between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients. Genes. 2019 May;10(5):364. PMID: 31083486 10.3390/genes10050364 Journal Article

Tanoshima R, Khan A, Biala AK, Trueman JN, Drögemöller BI, Wright GEB, Hasbullah JS, Groeneweg GSS, Ross CJD, Carleton BC. Analyses of Adverse Drug Reactions Nationwide Active Surveillance Network: Canadian Pharmacogenomics Network for Drug Safety (CPNDS) database. J Clin Pharmacol. 2019 Mar;59(3):356-363. PMID: 30452777 10.1002/jcph.1336 Journal Article

Drögemöller BI; Wright GEB; Shih J; Monzon JG; Gelmon KA; Ross CJD; Amstutz U; Carleton BC; The CPNDS Clinical Recommendations Group. CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines. Breast Cancer Res Treat. 2019; 173(3) 521-532 PMID: 30411242 10.1007/s10549-018-5027-0 Journal Article

Kowalec K; Wright GEB; Drögemöller BI; Aminkeng F; Bhavsar AP; Kingwell E; Yoshida EM; Traboulsee A; Marrie RA; Kremenchutzky M; Campbell TL; Duquette P; Chalasani N; Wadelius M; Hallberg P; Xia Z; De Jager PL; Denny JC; Davis MF; Ross CJD; Tremlett H; Carleton BC. Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis.  Nat Genet. 2018 Aug;50(8):1081-1085. PMID: 30013178 10.1038/s41588-018-0168-y Journal Article

Wright GE; Amstutz U; Drögemöller BI; Shih J; Rassekh SR; Hayden MR; Carleton BC; Ross CJD; Canadian Pharmacogenomics Network for Drug Safety Consortium. Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes. Clin Pharmacol Ther. 2019 Feb; 105(2); 402-410PMID: 29999516 10.1002/cpt.1179 Journal Article

Drögemöller BI; Brooks B; Critchley C; Monzon JG; Wright GEB; Liu G; Renouf DJ; Kollmannsberger CK; Bedard PL; Hayden MR; Gelmon KA; Carleton BC; Ross CJD. Further investigation of the role of ACYP2 and WFS1 pharmacogenomic variants in the development of cisplatin-induced ototoxicity in testicular cancer patients. Clin Cancer Res. 2018 Apr 15;24(8):1866-1871. PMID: 29358504 10.1158/1078-0432.CCR-17-2810 Journal Article

Wright GEB; Carleton B; Hayden MR; Ross CJD. The global spectrum of protein-coding pharmacogenomics diversity. Pharmacogenomics J. 2018 Jan;18(1):187-195. PMID: 27779249 10.1038/tpj.2016.77 Journal Article

Dionne F; Aminkeng F; Bhavsar AP; Groeneweg G; Smith A; Visscher H; Rassekh RS; Ross CJD; Carleton B. An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines. Pediatr Blood Cancer. 2018. PMID: 29271558 DOI: 10.1002/pbc.26887 Journal Article

Drögemöller BI; Monzon JG; Bhavsar AP; Borrie AE; Brooks B; Wright GEB; Liu G; Renouf DJ; Kollmannsberger CK; Bedard PL; Aminkeng F; Amstutz U; Hildebrand CA; Gunaretnam EP; Critchley C; Chen Z; Brunham LR; Hayden MR; Ross CJD; Gelmon KA; Carleton BC. Association between SLC16A5 genetic variation and cisplatin-induced ototoxic effects in adult patients with testicular cancer. JAMA Oncol. 2017 Nov 1;3(11):1558-1562. PMID: 28448657 10.1001/jamaoncol.2017.0502 Journal Article

Kowalec K; Kingwell E; Carruthers R; Marrie RA; Bernatsky S; Traboulsee A; Ross CJD; Carleton B; Helen Tremlett. Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia. BMJ Open 2017 Jun 2;7(5):e016276. PMID: 28576902 10.1136/bmjopen-2017-016276 Journal Article

Aminkeng F; Ross CJD; Rassekh SR; Rieder MJ; Bhavsar AP; Sanatani S; Bernstein D; Hayden MR; Amstutz U; Carleton BC. Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer. Br J Clin Pharmacol. 2017 May;83(5):1143-1145. PMID: 28317142 10.1111/bcp.13218 Journal Article

Jimenez R; Smith A; Carleton BC. New ways of detecting ADRs in neonates and children. Curr Pharm Des. 2015;21(39):5643-9. PMID: 26323415 10.2174/1381612821666150901105555 Journal Article

Shaw K; Amstutz U; Kim R; Lesko L; Turgeon J; Michaud V; Hwang S; Ito S; Ross C; Carleton BC. Clinical practice recommendations on genetic testing of CYP2C9 and VKORC1 variants in warfarin therapy. Ther Drug Monitoring. 2015 Aug;37(4):428-36.  PMID: 26186657 10.1097/FTD.0000000000000192 Journal Article

Kowalec K; Kingwell E; Yoshida EM; Marrie RA; Kremenchutzky M; Campbell TL; Wadelius M; Carleton B; Tremlett H. Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients. Expert Opin Drug Saf. 2014 Oct;13(10):1305-17. PMID: 25134421 10.1517/14740338.2014.947958    Journal Article

Smy L; Chan ACH; Bozzo P; Koren G, MD FRCPC FACMT. Is It Safe to Use Inhaled Corticosteroids in Pregnancy? Can Fam Physician. 2014 Sep;60(9):809-12,e433-5. PMID: 25217675. N/A Journal Article

Lee JW; Aminkeng F; Bhavsar AP; Shaw K; Carleton BC; Hayden MR; Ross CJD. The emerging era of pharmacogenomics: Current successes, future potential, and challenges. Clin Genet. 2014 Jul;86(1):21-8. PMID: 24684508 10.1111/cge.12392 Journal Article

Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Ped Blood Cancer. 2014 Jun;61(6):1055-62. PMID: 24474498 10.1002/pbc.24932 Journal Article

Amstutz U; Shear NH; Rieder MJ; Hwang S; Fung V; Nakamura H; Connolly MB; Ito S; Carleton BC. The CPNDS Clinical Recommendation Group. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia. 2014 Apr;55(4):496-506. PMID: 24597466  10.1111/epi.12564 Journal Article

Madadi P; Amstutz U; Rieder M; Ito S; Fung V; Hwang S; Turgeon J; Michaud V; Koren G; Carleton BC. Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy. J Popul Ther Clin Pharmacol. 2013 Nov; 20(3): e369-e396. PMID: 24214521 N/A Journal Article

Pussegoda K; CJ Ross; Visscher H; Yazdanpanah M; Brooks B; Rassekh SR; Zada YF; Dubé MP; Carleton BC; Hayden MR; CPNDS Consortium. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther. 2013 Aug;94(2):243-51. PMID: 23588304 10.1038/clpt.2013.80 Journal Article

Amstutz U; CJD Ross; Castro-Pastrana LI; Rieder MJ; Shear NH; Hayden MR; Carleton BC; CPNDS Consortium. HLA-A*31:01 and HLA-B*15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin Pharmacol Ther. 2013 Jul;94(1):142-9.  PMID: 23588310 10.1038/clpt.2013.55 Journal Article

Kowalec K; Carleton B; Tremlett H. The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis. Multiple Sclerosis and Related Disorders. 2013 Jul;2(3):183-192. 10.1016/j.msard.2012.11.003 Journal Article

Shaw K; Amstutz U; Castro-Pastrana L; Loo TT; Ross CJ; Ito S; Rieder MJ; Maher M; MacLeod S; Koren G; Hayden MR; Carleton BC. Pharmacogenomic investigation of adverse drug reactions: the ADR prioritization tool, APT.  J Popul Ther Clin Pharmacol. 2013 June;20(2):e110-127. PMID: 23824325 N/A Journal Article

Kowalec K; Yoshida EM; Traboulsee A; Carleton B; Tremlett H. Suspected autoimmune hepatitis and primary biliary cirrhosis unmasked by interferon-beta in a multiple sclerosis patient. Mult Scler Relat Disord. 2013 Jan;2(1):57-59. 10.1016/j.msard.2012.07.004 Journal Article

Shaw K; Amstutz U; Jimenez-Mendez R; Ross CJ; Carleton B. Suspected opioid overdose case resolved by CYP2D6 genotyping. Ther Drug Monit. 2012 Apr;34(2):121-3. PMID: 22406651 10.1097/FTD.0b013e31824a1e21 Journal Article

Shaw K; Amstutz U; Carleton BC. Using pharmacogenetics to understand adverse drug reactions in children. Paediatr Child Health. 2011 Nov; 6(9):537-8 PMID: 23115490 10.1093/pch/16.9.537 Journal Article

Visscher H; Amstutz U; Sistonen J; Ross C; Hayden M; Carleton B. Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics. J Cardiovasc Pharmacol. 2011 Sep;58(3):228-39. PMID: 21386709 10.1097/FJC.0b013e3182163b82 Journal Article

Amstutz U; Carleton BC. Pharmacogenetic testing: time for clinical practice guidelines. Clin Pharmacol Ther. 2011 Jun;89(6):924-7. PMID: 21508939 10.1038/clpt.2011.18 Journal Article